Ecdysone receptor (EcR) domain of the Gal4-EcR fusion protein (EcR)

The EcR domain of the Gal4-EcR fusion protein is a central regulatory component of the RheoSwitch Therapeutic System (RTS), an inducible gene expression platform designed for precise control of therapeutic transgenes [1]. This domain is typically derived from the ecdysone receptor of the spruce budworm (Choristoneura fumiferana), a member of the nuclear receptor superfamily that naturally responds to ecdysteroid hormones in insects [2]. In the RTS architecture, the EcR ligand-binding domain (LBD) is fused to a yeast Gal4 DNA-binding domain to create a chimeric transactivator. When a synthetic small-molecule ligand, such as Veledimex, is administered, it binds to the EcR domain, inducing a conformational change that facilitates heterodimerization with a partner protein, often a chimeric Retinoid X Receptor [3]. This complex then binds to specific upstream activating sequences (UAS) to initiate the transcription of a linked therapeutic gene, such as Interleukin-12 (IL-12), in a dose-dependent manner [4]. This system is primarily utilized in oncology to manage the expression of potent cytokines, minimizing systemic toxicity while maximizing local therapeutic effects [5].

Other names

RheoSwitch Therapeutic SystemRTSGal4-EcR chimeric transactivatorEcdysone receptor ligand-binding domainEcR-LBD

The EcR domain acts as a molecular switch that, upon binding to a specific small-molecule inducer (e.g., Veledimex), undergoes a conformational change allowing the Gal4-EcR fusion protein to dimerize with a partner protein and bind to DNA, thereby initiating the transcription of a downstream therapeutic transgene.